CCP
IBRX icon

Clough Capital Partners’s ImmunityBio IBRX Stock Holding History

Clough Capital Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.5M Buy
399,216
+305,175
+325% +$2.31M 0.28% 56
2026
Q1 		$721K Buy
+94,041
New +$644K 0.07% 94

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clough Capital Partners's IBRX Position: Q2 2026 in Review

Clough Capital Partners increased its ImmunityBio (IBRX) stake by 325% in Q2 2026, buying an estimated $2.31M and bringing the position to 399,216 shares worth $3.5M. The position accounts for 0.28% of the portfolio, ranked #56.

Clough Capital Partners first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Clough Capital Partners held 399,216 shares of ImmunityBio worth $3.5M as of Q2 2026.
  • Clough Capital Partners bought 305,175 ImmunityBio shares in Q2 2026, an estimated $2.31M.
  • ImmunityBio made up 0.28% of Clough Capital Partners's portfolio in Q2 2026, its #56 holding.
  • Clough Capital Partners first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Clough Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.